Καρδιολογική Γνώμη - Εθνικό και Καποδιστριακό Πανεπιστήμιο ...

108 Π. Ντετοπούλου και συν.Βιβλιογραφία1. Stafforini DM, McIntyre TM, Zimmerman GA, Prescott SM. Plateletactivatingfactor, a pleiotrophic mediator of physiological and pathologicalprocesses. Crit Rev Clin Lab Sci 2003; 40:643-72.2. Demopoulos C, Karantonis H, Antonopoulou S. Platelet activatingfactor - a molecular link between atherosclerosis theories. Eur J LipidSci Technol 2003; 105:705-716.3. Snyder F. Platelet-activating factor and its analogs: metabolic pathwaysand related intracellular processes. Biochim Biophys Acta 1995;1254:231-49.4. Shindou H, Hishikawa D, Nakanishi H, et al. A single enzyme catalyzesboth platelet-activating factor production and membrane biogenesisof inflammatory cells. Cloning and characterization of acetyl-CoA:lyso-PAFacetyltransferase. J Biol Chem 2007; 282:6532-9.5. Snyder F. CDP-choline:alkylacetylglycerol cholinephosphotransferasecatalyzes the final step in the de novo synthesis of platelet-activatingfactor. Biochim Biophys Acta 1997; 4:111-6.6. Harayama T, Shindou H, Ogasawara R, Suwabe A, Shimizu T. Identificationof a novel noninflammatory biosynthetic pathway of platelet-activatingfactor. J Biol Chem 2008; 283:11097-106.7. Stafforini DM. Biology of platelet-activating factor acetylhydrolase(PAF-AH, lipoprotein associated phospholipase A2). CardiovascDrugs Ther 2009; 23:73-83.8. Tellis CC, Tselepis AD. The role of lipoprotein-associated phospholipaseA(2) in atherosclerosis may depend on its lipoprotein carrier inplasma. Biochim Biophys Acta 2009; 1971:327-338.9. Thompson A, Gao P, Orfei L, et al. Lipoprotein-associated phospholipaseA(2) and risk of coronary disease, stroke, and mortality: collaborativeanalysis of 32 prospective studies. Lancet 375:1536-44.10. Detopoulou P, Nomikos T, Fragopoulou E, Stamatakis G, PanagiotakosDB, Antonopoulou S. PAF and its metabolic enzymes in healthy volunteers:Interrelations and correlations with basic characteristics.Prostaglandins Other Lipid Mediat 2012; 97:43-49.11. Demopoulos CA, Andrikopoulos NK, Antonopoulou S. A simple andprecise method for the routine determination of platelet-activatingfactor in blood and urine. Lipids 1994; 29:305-9.12. Nathan N, Denizot Y, Huc MC, et al. Elevated levels of paf-acetherin blood of patients with type 1 diabetes mellitus. Diabete Metab1992; 18:59-62.13. Izaki S, Yamamoto T, Goto Y, et al. Platelet-activating factor andarachidonic acid metabolites in psoriatic inflammation. Br J Dermatol1996; 134:1060-4.14. Labrakis-Lazanas K, Lazanas M, Koussissis S, Tournis S, DemopoulosCA. PAF of biological fluids in disease: blood levels in allergic rhinitis.Haematologica 1988; 73:379-82.15. Denizot Y, Desplat V, Drouet M, Bertin F, Melloni B. Is there a roleof platelet-activating factor in human lung cancer? Lung Cancer 2001;33:195-202.16. Antonopoulou S, Tsoupras A, Baltas G, Kotsifaki H, Mantzavinos Z,Demopoulos CA. Hydroxyl-platelet-activating factor exists in bloodof healthy volunteers and periodontal patients. Mediators Inflamm2003; 12:221-7.17. Demopoulos CA, Lazanas M, Labrakis-Lazanas K. PAF of biologicalfluids in disease: I. Levels in blood and urine in cancer. Clin Chem EnzymComms 1990; 3:41-47.18. Yang YM, Cao HC, Xu ZR, Chen XM. Creation of reversed phase high-performanceliquid chromatographic technique to assay plateletactivatingfactor. J Zhejiang Univ Sci 2004;5:738-42.19. Cao HC, Chen XM, Xu W. Determination of platelet-activating factorby reverse phase high-performance liquid chromatography and its applicationin viral hepatitis. World J Gastroenterol 2005; 11:7364-7.20. Tselepis AD, Panagiotakos DB, Pitsavos C, Tellis CC, Chrysohoou C,Stefanadis C. Smoking induces lipoprotein-associated phospholipaseA2 in cardiovascular disease free adults: the ATTICA Study. Atherosclerosis2009; 206:303-8.21. Baker PR, Owen JS, Nixon AB, et al. Regulation of platelet-activatingfactor synthesis in human neutrophils by MAP kinases. Biochim BiophysActa 2002; 1592:175-84.22. Misso NL, Gillon RL, Stewart GA, Thompson PJ. Lyso-PAF acetyltransferaseactivity in neutrophils of patients during acute asthma andafter recovery. Eur Respir J 1996; 9:2243-9.23. Detopoulou P, Nomikos T, Fragopoulou E, et al. Platelet activatingfactor (PAF) and activity of its biosynthetic and catabolic enzymes inblood and leukocytes of male patients with newly diagnosed heartfailure. Clin Biochem 2009;42:44-9.24. Tsoupras AB, Fragopoulou E, Nomikos T, Iatrou C, Antonopoulou S,Demopoulos CA. Characterization of the de novo biosynthetic enzymeof platelet activating factor, DDT-insensitive cholinephosphotransferase,of human mesangial cells. Mediators Inflamm 2007;2007:27683.25. Tsantila N, Tsoupras AB, Fragopoulou E, Antonopoulou S, Iatrou C,Demopoulos CA. In vitro and in vivo effects of statins on platelet-activatingfactor and its metabolism. Angiology 2011;62:209-18.26. Bussolino F, Sironi M, Bocchietto E, Mantovani A. Synthesis of platelet-activatingfactor by polymorphonuclear neutrophils stimulatedwith interleukin-8. J Biol Chem 1992; 267:14598-603.27. Valone FH, Epstein LB. Biphasic platelet-activating factor synthesisby human monocytes stimulated with IL-1-beta, tumor necrosis factor,or IFN-gamma. J Immunol 1988; 141:3945-50.28. Tosaki T, Sakamoto H, Kitahara J, Imai H, Nakagawa Y. Enhancementof acetyl-CoA: 1-O-alkyl-2-lyso-sn-glycero-3-phosphocholine acetyltransferaseactivity by hydrogen peroxide. Biol Pharm Bull 2007;30:272-8.29. Heller R, Bussolino F, Ghigo D, Garbarino G, Pescarmona G, Till U.Stimulation of platelet-activating factor synthesis in human endothelialcells by activation of the de novo pathway. Phorbol 12-myristate 13-acetate activates 1-alkyl-2-lyso-sn-glycero-3-phosphate:Acetyl-CoAacetyltransferase and dithiothreitol-insensitive 1-alkyl-2-acetyl-snglycerol:CDP-cholinecholinephosphotransferase. J Biol Chem 1991;266:21358–61.30. Ibe BO, Portugal AM, Usha Raj J. Metabolism of platelet activatingfactor by intrapulmonary vascular smooth muscle cells. Effect of oxygenon phospholipase A2 protein expression and activities of acetyl-CoA acetyltransferase and cholinephosphotransferase. Mol GenetMetab 2002; 77:237-48.31. Nieto ML, Velasco S, Sanchez Crespo M. Biosynthesis of platelet-activatingfactor in human polymorphonuclear leukocytes. Involvementof the cholinephosphotransferase pathway in response to the phorbolesters. J Biol Chem 1988; 263:2217-22.32. Ρεκλείτη Ε. Μεταπτυχιακή Διατριβή: Επίδραση μικροθρεπτικών συστατικώντης μεσογειακής δίαιτας στη σύνθεση του παράγοντα ενεργοποίησηςαιμοπεταλίων (PAF) από ανθρώπινα μεσαγγειακά κύτταρα.Τμήμα Επιστήμης Διαιτολογίας- Διατροφής. Αθήνα: Χαροκόπειο Πανεπιστήμιο,2006.33. Βλαχογιάννη Ι. Ερευνητική εργασία διπλώματος ειδίκευσης: Μελέτητης επίδρασης εκχυλίσματος ελαιολάδου στην επαγόμενη από σύνθεσηPAF σε κυτταρική σειρά μονοκυττάρων. Εθνικό και ΚαποδιστριακόΠανεπιστήμιο Αθηνών. Αθήνα, 2009.34. Gomes MB, Cobas RA, Nunes E, Nery M, Castro-Faria-Neto HC, TibiricaE. Serum platelet-activating factor acetylhydrolase activity: anovel potential inflammatory marker in type 1 diabetes. ProstaglandinsOther Lipid Mediat 2008; 87:42-6.35. Zhang X, Yuan CL, Zhang HZ, Huang RX. Age-related increase of plasmaplatelet-activating factor concentrations in Chinese. Clin ChimActa 2003; 337:157-62.36. Kudolo GB, Koopmans SJ, Haywood JR, DeFronzo RA. Chronic hyperinsulinemiainhibits platelet-activating factor (PAF) biosynthesis inthe rat kidney. J Lipid Mediat Cell Signal 1997; 16:23-37.37. Hines KL, Braillon A, Fisher RA. PAF increases hepatic vascular resistanceand glycogenolysis in vivo. Am J Physiol 1991; 260:G471-80.38. Daniels LB, Laughlin GA, Sarno MJ, Bettencourt R, Wolfert RL, Barrett-ConnorE. Lipoprotein-associated phospholipase A2 is an independentpredictor of incident coronary heart disease in an apparently